Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telmisartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 6/20 | 0.98 |
| ▸ | PPARG | P37231 | 4/20 | 0.98 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | ACE | P12821 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telmisartan SCHEMBL2122886 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29356790 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29414101 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL4464 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29691699 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL1071821 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL3384004 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL998659 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29113697 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29032036 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115245497-A | Telmisartan capsule and preparation process thereof | 武汉伯睿科医药科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| EP-2046756-A2 | PREPARATION OF TELMISARTAN SALTS | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2009-04-15 | — | — | EP | claimed |
| WO-2007147889-A2 | PREPARATION OF TELMISARTAN SALTS | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2007-12-27 | — | — | WO | claimed |
| CN-115245497-A | Telmisartan capsule and preparation process thereof | 武汉伯睿科医药科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-112791085-A | Preparation method of telmisartan preparation intermediate | 南京国星生物技术研究院有限公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-112603898-A | Telmisartan tablet and preparation method thereof | 苏州中化药品工业有限公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-2252273-B1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING A NON-PEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC | RATIOPHARM GMBH (DE) | 2016-12-28 | — | — | EP | disclosed |
| CN-105726502-A | Telmisartan tablet | 南京多宝生物科技有限公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-105726500-A | Telmisartan tablets and preparation method thereof | 南京正亮医药科技有限公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-103142596-B | Medicinal composition containing telmisartan and pitavastatin | UNIV SICHUAN | 2015-05-06 | — | — | CN | disclosed |
| CN-103800295-A | Telmisartan preparation and preparation method thereof | QINGDAO KDN BIOTECH CO LTD | 2014-05-21 | — | — | CN | disclosed |
| EP-2046756-A2 | PREPARATION OF TELMISARTAN SALTS | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2009-04-15 | — | — | EP | disclosed |
| EP-2046756-A2 | PREPARATION OF TELMISARTAN SALTS | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2009-04-15 | — | — | EP | disclosed |
| EP-1805146-A4 | PROCESS FOR PREPARING TELMISARTAN | REDDYS LAB LTD DR (IN) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007147889-A3 | PREPARATION OF TELMISARTAN SALTS | KRKA TOVARNA ZDRAVIL D D NOVO (SI) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007147889-A2 | PREPARATION OF TELMISARTAN SALTS | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147889-A2 | PREPARATION OF TELMISARTAN SALTS | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2007-12-27 | — | — | WO | disclosed |
| US-20070287840-A1 | Process for Preparing Telmisartan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-12-13 | — | — | US | disclosed |
| EP-1805146-A2 | PROCESS FOR PREPARING TELMISARTAN | Dr. Reddy's Laboratories Ltd. (IN) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044754-A2 | PROCESS FOR PREPARING TELMISARTAN | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287840-A1 | Process for Preparing Telmisartan | AGT, TTR, REN | AGTR1 4/4885PPARG 2394/4885AGTR2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.